Home » Topics » Regulatory » EMA

EMA
RSS

Theratechnologies gives update on tesamorelin regulatory progress

June 25, 2012

European CHMP adopts opinion on teduglutide

June 25, 2012

Alexza provides update on Adasuve submissions

June 25, 2012

EMA validates MAAs for fixed-dose combination diabetes therapies

June 20, 2012

Investigational gene therapy gets orphan drug status for adrenoleukodystrophy

June 20, 2012

EMA to conduct centralized review of elvitegravir MAA

June 19, 2012

Genta reaches agreement on phase III tesetaxel trial

June 19, 2012

EMA's COMP issues opinion on Enhoxy

June 14, 2012

AR-42 gets E.U. orphan drug status for two additional indications

June 8, 2012

CHMP schedules hearing for Vivus' Qnexa MAA

June 6, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...